{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"0.0"},{"groupId":"OG001","spread":"0.0","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"The number of events of osteonecrosis of jaw was averaged across all participants, including those participants who did not experience the event during the study.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"MEAN","populationDescription":"ITT Population.","reportingStatus":"POSTED","timeFrame":"From Baseline to end of study (up to Week 96)","title":"Number of Events of Osteonecrosis of Jaw for Each Participant","type":"SECONDARY","unitOfMeasure":"events of osteonecrosis of jaw"}